Immune Pharmaceuticals, Inc. (NASDAQ: IMNP) applies a personalized approach to treating and, developing novel, highly-targeted antibody therapeutics to potentially improve the lives of patients with inflammatory diseases and cancer, and the Company's lead product candidate, bertilimumab, is in clinical development for moderate to severe ulcerative colitis and Crohn's disease as well as bullous pemphigoid, an orphan auto-immune dermatological condition, according the company’s website (see here: www.ImmunePharmaceuticals.com). SNNLive caught up with Dr. Daniel Teper, CEO of Immune Pharmaceuticals, Inc., at the Dawson James Small Cap Growth Conference 2015 in Jupiter, FL.
In this video interview, Dr. Teper and our host discuss the following conditions:
- Overview of Immune Pharmaceuticals, Inc.
- Update since our last interview in June 2015
- Discusses clinical and corporate developments
- The company’s science and technology
- Dr. Teper’s background
For more information about Immune Pharmaceuticals, Inc., go to:
© 2017 Stock News Now
Supported by Superior Web Solutions